Company News
Verastem Shares Fall 5% on Trial Data
Verastem stock fell about 5% in after‑hours trading after releasing early Phase 1/2 data for its KRAS G12D inhibitor VS‑7375.
In the pancreatic cohort, 93% of 14 heavily pretreated patients on 900 mg
